NCT00536107View on ClinicalTrials.gov

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

PHASE4TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Gefitinib

250 mg oral

PROCEDURE

CT or MRI

performed at screening and every 6 weeks

DRUG

Docetaxel

60mg/m2 intravenous infusion

Trial Locations (1)

Unknown

Research Site, Taipei

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY